Apigenin

The CD38 inhibition by apigenin is established in preclinical research — Escande 2013 (PMID 23603845) demonstrated apigenin inhibits CD38 with IC50 in the low micromolar range (approximately 10 micromolar) and administration to aged mice restored NAD+ levels in liver, muscle, and white adipose tissue toward young-adult concentrations. However, direct human clinical trials measuring plasma or tissue NAD+ levels in response to purified apigenin supplementation are sparse. The NAD+-boosting claim in humans relies largely on extrapolation from mouse data to expected pharmacokinetic-tissue exposure in humans at comparable supplementation doses (100-250 mg daily). This mechanistic extrapolation is reasonable but not clinically validated in large randomized human trials specifically measuring NAD+. Practically: users pursuing NAD+ optimization should prioritize NR or NMN (which have direct human evidence for blood NAD+ elevation), and add apigenin as a theoretically-synergistic CD38 inhibitor with the understanding that the human efficacy is mechanistically-justified but not yet robustly clinically documented. Combining apigenin 100-250 mg daily with NR or NMN is a reasonable approach based on complementary mechanisms.

The appropriate apigenin dose depends on the target effect. For sleep and mild calming via GABA-A receptor modulation: 50-100 mg 30-60 minutes before bedtime, or 1-2 cups of chamomile tea. For NAD+ preservation stack with NR or NMN: 100-250 mg daily with breakfast. For comprehensive polyphenol longevity stack: 250-500 mg daily split between breakfast and lunch. For research-dose use targeting specific inflammatory or chemopreventive claims: 500-1000 mg daily. Most commercial products provide 50-500 mg per capsule. Doses below 100 mg are suitable for entry-level sleep support; doses of 100-250 mg are optimal for the NAD+/longevity-oriented applications; doses above 500 mg daily should be pursued only with clinical context or specific research goals. Chamomile tea (providing 1-6 mg apigenin per cup depending on preparation) is a traditional entry point with generations of safe use and is reasonable for users seeking mild calming without supplemental pill use.

Apigenin, quercetin, and fisetin are all flavonoids but belong to different subclasses with distinct structural and functional profiles. Quercetin is a flavonol (3,3',4',5,7-pentahydroxyflavone — five hydroxyl groups). Fisetin is also a flavonol (3,3',4',7-tetrahydroxyflavone — four hydroxyl groups, one less than quercetin). Apigenin is a flavone (4',5,7-trihydroxyflavone — three hydroxyl groups, lacking the 3-OH of flavonols). Functional differences: Quercetin has stronger mast cell stabilization and histamine reduction, strong zinc ionophore activity, and moderate antioxidant potency. Fisetin is the most potent natural senolytic (clears senescent cells), has superior BBB penetration, and has been tested in lifespan extension studies in aged mice. Apigenin has unique CD38 inhibition (preserving NAD+), GABA-A receptor binding (calming effects), and distinctive anticancer signaling patterns. For users pursuing comprehensive flavonoid coverage, the three can be stacked: quercetin for chronic daily anti-inflammatory and immune support, fisetin for intermittent senolytic pulse dosing (1400 mg for 2 days monthly), and apigenin for chronic daily NAD+ preservation and calming support. The three complement rather than replace each other. Users selecting a single flavonoid should match the compound to the primary goal: quercetin for allergies/mast cell issues, fisetin for senolytic/longevity-lifespan, apigenin for NAD+/calming/general polyphenol support.

For GABA-A-mediated calming and sleep effects, chamomile tea at conventional consumption (1-2 cups 30-60 minutes before bedtime) provides sufficient apigenin and other chamomile constituents for most users seeking mild anxiolytic or sleep-promoting effects. Amsterdam 2009 and related chamomile clinical trials validated chamomile extract (standardized for apigenin) for generalized anxiety disorder, and culinary chamomile tea has generations of safe use. A cup of chamomile tea provides approximately 1-6 mg of apigenin along with other bioactive flavonoids. For GABA-A applications, supplementation with 50-100 mg purified apigenin provides substantially more apigenin than tea but is functionally equivalent for most users — the threshold for GABA-A-mediated relaxation is relatively low. For applications beyond GABA-A effects — specifically CD38 inhibition for NAD+ preservation and higher-dose anti-inflammatory effects — purified supplementation at 100-500 mg daily provides therapeutically-meaningful doses that are impractical to achieve through chamomile tea alone (would require 50+ cups daily). Practical recommendation: if your goal is sleep support, chamomile tea is a reasonable starting point. If your goal is NAD+ preservation or longevity-oriented polyphenol coverage, purified apigenin supplements are more efficient. Users can combine both (chamomile tea plus apigenin supplement) without concerns.

Yes, apigenin has a favorable long-term safety profile based on multiple lines of evidence. Dietary apigenin (from parsley, chamomile, celery, artichokes) has been consumed by humans for thousands of years without documented chronic toxicity. Chamomile tea has generations of safe use including long-term daily consumption. Purified apigenin supplementation studies of months' duration have reported good tolerance at doses up to 500-1000 mg daily. The primary long-term concerns involve: (1) potential drug interactions via CYP enzyme modulation for individuals on narrow-therapeutic-index medications, (2) weak phytoestrogen activity in estrogen-dependent cancer contexts at high doses, (3) theoretical antiplatelet effects requiring surgery-period discontinuation, (4) cross-reactivity in individuals with Asteraceae family allergies (ragweed, chamomile). For healthy adults at doses of 50-250 mg daily, long-term daily supplementation is reasonable without expected safety concerns. Regular monitoring with annual comprehensive metabolic panel and complete blood count is prudent, particularly at higher doses or with polypharmacy.

Apigenin binds to benzodiazepine binding sites on GABA-A receptors as a partial agonist, and theoretically its GABA-A effects could be additive with pharmacological sedatives. At conventional chamomile tea doses (1-2 cups), the GABA-A stimulation is sufficiently modest that additive sedation with benzodiazepines, Z-drugs (zolpidem, zaleplon, eszopiclone), or alcohol is unlikely to be clinically significant in most users. At higher apigenin supplementation doses (100-500 mg daily), the theoretical additive sedation concern becomes more relevant. Practical recommendations: (1) users on occasional benzodiazepines (e.g., for acute anxiety episodes) can typically use conventional chamomile tea without concern but should avoid high-dose apigenin supplements on the same day as benzodiazepine dose; (2) users on chronic benzodiazepine therapy should keep apigenin at chamomile-tea levels only and discuss with their prescribing physician; (3) users on Z-drug therapy for insomnia can reasonably pair with evening chamomile tea but should avoid higher-dose apigenin supplements; (4) alcohol with apigenin — single-drink occasional use with chamomile tea is generally safe; heavy or chronic alcohol use combined with high-dose apigenin supplementation should be avoided. Consult your prescribing physician if you take daily benzodiazepines, Z-drugs, or other GABA-modulating medications.

The Sirtfood Diet, popularized by Aidan Goggins and Glen Matten in a 2016 book, proposes that consumption of foods high in polyphenols that activate sirtuin enzymes can promote weight loss and longevity. Apigenin-rich foods like parsley, celery, and red onions are prominent in the diet's recommended food list alongside other polyphenol-rich foods (green tea, dark chocolate, turmeric, red wine, walnuts, capers, lovage, kale, strawberries). The theoretical mechanism combines SIRT1 activation (from various polyphenols including resveratrol, pterostilbene, and apigenin) with caloric restriction for claimed enhanced metabolic effects. The scientific basis for specific sirtuin-activating properties of the Sirtfood list is mixed — some compounds (resveratrol, pterostilbene) have documented SIRT1 activation, while others are primarily antioxidants without specific sirtuin-targeting activity. Apigenin's contribution to sirtuin-related effects is primarily through CD38 inhibition and NAD+ preservation (providing substrate for sirtuins) rather than direct sirtuin activation. Overall assessment: the Sirtfood Diet emphasizes polyphenol-rich foods that have independent health benefits for cardiovascular, metabolic, and cognitive outcomes. The specific sirtuin-targeting mechanism claims are partially supported but not sufficient to recommend the diet uniquely for that mechanism. The diet's emphasis on vegetables, fruits, moderate calories, and polyphenol-rich foods is consistent with general healthy eating guidelines independent of sirtuin claims.

Apigenin has been extensively studied in preclinical cancer models across multiple tumor types including breast, prostate, colon, lung, pancreatic, ovarian, and head-and-neck cancers. Mechanisms include cell cycle arrest through p21 and p27 upregulation, apoptosis induction through Bcl-2 family modulation, PI3K/Akt/mTOR pathway inhibition, NF-kB suppression, antiangiogenic effects, and epigenetic modulation. Specific studies include Shukla 2014 (PMID 24957915) in prostate cancer TRAMP mice, Camacho-Alonso 2019 (PMID 30904672) in head and neck cancer models, and numerous in vitro studies showing preferential cytotoxicity for cancer cells versus normal cells. However, clinical translation to established human cancer prevention or treatment is limited. Pilot studies in cancer patients have been small and inconclusive. Major clinical research organizations do not currently recommend apigenin supplementation as standard cancer prevention or treatment. Practical stance: users with cancer history or active cancer should not use apigenin supplementation without oncology team input. Apigenin is appropriately positioned as a dietary and moderate-dose supplementation polyphenol with anti-inflammatory and longevity-oriented activities, not as a cancer-specific intervention. Users interested in diet-based cancer risk reduction should focus on evidence-based approaches (Mediterranean diet, weight management, physical activity, tobacco avoidance) rather than specific apigenin supplementation.

Apigenin is molecularly identical regardless of source — pure isolated apigenin from parsley, chamomile, passiflora, or synthetic origin is the same compound with identical pharmacology. Source preferences relate primarily to: (1) allergic cross-reactivity — individuals with Asteraceae family (ragweed, chamomile, daisy) allergies should avoid chamomile-source products and prefer parsley-derived or passiflora-derived; (2) co-extracted constituents — whole-herb extracts may contain other bioactive compounds alongside apigenin (chamomile has bisabolol, chamazulene; passiflora has other flavonoids; parsley has apiol and other constituents), which may provide additional effects or add variability; (3) manufacturing quality — source-dependent contamination risks (pesticide residues, heavy metals, adulterants) vary by source and manufacturer; prefer products with third-party purity testing; (4) purity standardization — products specifying >95% pure isolated apigenin are preferred over lower-purity extracts for applications requiring dose-predictability. For most users, source selection is a minor consideration; quality standardization and purity verification are more important. For users with specific allergies or those wanting whole-herb activity alongside apigenin, source does matter. Cost differences between sources are typically modest.

Apigenin's effects develop on different timescales depending on the target outcome. Pharmacokinetic effects (plasma levels) are immediate, with peak concentrations within 1-2 hours of a dose. GABA-A-mediated calming effects are subjectively apparent within 30-90 minutes of a dose — this is why chamomile tea 30-60 minutes before bedtime is effective for sleep support. CD38 inhibition for NAD+ preservation requires chronic dosing (days to weeks) for measurable effects on tissue NAD+ levels. Anti-inflammatory biomarker effects (CRP, IL-6 reduction) develop over weeks to months of consistent supplementation. Longevity-oriented effects require months to years of continuous use and cannot be assessed over short intervals. Timing recommendations: for sleep and calming, take apigenin 30-60 minutes before bedtime; for NAD+ preservation and morning energy support, take with breakfast; for comprehensive polyphenol stack alongside breakfast supplements, combine with morning routine. Discontinuation: apigenin's effects are fully reversible with discontinuation — subjective GABA-A effects disappear within hours, biomarker effects within weeks. No withdrawal syndrome or rebound phenomenon occurs. Users can start, stop, and restart apigenin without special tapering. Consistency over months matters more than perfect daily adherence for longevity-oriented applications.